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ABSTRACT
Assays of Factor VIII in clinical laboratories are subject to large variability and one of the sources of
this variability is the wide range of reference plasmas used. An International Standard for Factor VIII
in plasma is available from WHO but only in limited quantity. The aim of this project was to establish
a European Reference Plasma for Factor VIII, carefully calibrated against the WHO standard in a
large collaborative study, in order to improve quality control in European laboratories.
The European Reference Plasma for Factor VIII (BCR-629) consists of lyophilised normal human
plasma, pooled from 17 donors, in sealed glass ampoules. Prior to pooling and ampouling the
plasmas were centrifuged twice and buffered in order to enhance stability, according to previous
studies.
BCR-629 has been calibrated for FVIII relative to the primary WHO International Standard for
FVIII in plasma (3rd International Standard Factor VIII/vWF, plasma code 91/666) in a
collaborative study involving 14 laboratories in 10 countries. There was good agreement between
laboratories and between the 1-stage and chromogenic assay methods. Preliminary stability studies
based on accelerated degradation predicted satisfactory long term stability for the standard when
stored at –20 oC, but further monitoring of stability in real time will be performed.
The results of the calibration study indicated that preparation BCR-629 is suitable to serve as the
European Reference Plasma for Factor VIII.
The assigned value for BCR-629 is as follows:
Material Mean potency1)
(IU per
ampoule)
Uncertainty2)
(IU per
ampoule)
No of
accepted
results
BCR-629 Reference Plasma for Factor
VIII
0.70 0.02 17
1)
 This result is the unweighted geometric mean from 17 independent estimates
2) The uncertainty is given as the half width of the 95% confidence interval of the mean defined in 1)
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LIST OF ABBREVIATIONS AND SYMBOLS
APTT activated partial thromboplastin time
CV coefficient of variation
EQAS external quality assurance scheme
FVIII coagulation factor VIII
FVIII:C coagulation factor VIII: clotting activity
GCV geometric coefficient of variation
HBsAg Hepatitis B surface particle antigen
HCV Hepatitis C virus
HEPES N-[2-Hydroxyethyl]piperazine-N'-[2-
ethanesulfonic acid]
HIV human immune deficiency virus
ICSH International Committee on Standards in
Haematology
ISTH International Society on Thrombosis and
Haemostasis
IU International Unit
SSC Scientific and Standardisation Committee
vWF von Willebrand factor
WHO World Health Organisation
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71. INTRODUCTION
1.1 Background and need for a CRM
Testing of patients' blood samples for various coagulation indices is an important aspect of the
diagnosis and treatment of disorders of coagulation. Assays of Factor VIII (FVIII) are mainly
carried out in association with diagnosis and treatment of haemophilia A, caused by genetic
deficiency of FVIII, but are also performed in relation to acquired coagulation defects and to
epidemiological studies of normal individuals.
Coagulation measurements are generally recognised to suffer from large variability. This is partly
because of the biological nature of the test samples and reagents, and partly because of the
multiplicity of reagents available. Standardisation is exerted at international level, by the provision of
reference standards by the World Health Organisation (WHO), co-ordinated through the Scientific
and Standardisation Committee (SSC) of the International Society on Thrombosis and Haemostasis
(ISTH) and the International Committee on Standards in Haematology (ICSH), and of reference
methods and guidelines provided by the ISTH and ICSH. At Community level, laboratories have
access to WHO standards, but these are only available in limited quantities and therefore need to be
supplemented with national, local, and commercial standards. An additional level of national control
is the operation of external quality assurance schemes (EQAS), in which results of different
laboratories are compared.
Although an international plasma standard for FVIII has been available for factor VIII assays since
1981 (1, 2), considerable interlaboratory variability still exists, as can be judged from results from
UK EQAS surveys, showing a wide distribution of results, with coefficients of variation (CV) of 20-
30%. Analysis of results according to the various reference plasmas used indicates that the different
reference plasmas are a major source of variability. This is also suggested by the fact that, in an
international collaborative study, using a common reference plasma, interlaboratory CVs were less,
around 11% (3). The availability of a European reference plasma would allow much more extensive
calibration of commercial plasmas, and, unlike the WHO standard, could also be used for quality
control in laboratories of member states.
1.2 Choice of Material
The most suitable material for a FVIII reference plasma is fresh normal plasma from a Blood
Transfusion Centre, collected and treated in a manner designed to preserve the biological activity of
FVIII (see also Section 4.1). A description of the actual material used and the method of processing
is in Sections 4.2 and 4.3.
1.3 The International Unit for Factor VIII
The International Unit is defined as the amount of FVIII found in 1 mL of fresh, pooled normal
human plasma. The original 1st International Standard Factor VIII/vWF plasma (code 80/511) was
calibrated relative to freshly collected normal plasma pools comprising a total of 315 donors in a
multi-centre collaborative study (1). In this study the local fresh plasma pools were arbitrarily
assigned a unitage of 1 IU per mL. The 3rd International Standard Factor VIII/vWF, plasma (code
91/666) was calibrated in a study which allowed comparison with the previous 2nd International
Standard and also freshly collected normal plasma pools to ensure continuity of the International Unit
(3). A mean value of 0.80 IU per ampoule (95% confidence limits 0.78 - 0.83) was assigned to the
3rd International Standard based on the results from 14 laboratories. This was the WHO standard in
use at the time of calibration of the BCR reference plasma; it has recently been replaced by the 4th
International Standard (1998). The traceability of successive International Standards is shown in
Figure 1.1.
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Figure 1.1 – Traceability scheme of the international unit (IU) for Factor VIII
1.4 Design of the Collaborative Study
The objective of the collaborative study was to assign a value in International Units (IU) to the
proposed European reference plasma BCR-629 by assay relative to the existing WHO reference
plasma for FVIII (3rd International Standard Factor VIII/vWF, plasma, code 91/666). Details of
the protocol and methodology are given in Section 7.
1.5 Original Definition
One International Unit (IU) of Factor VIII is the amount in 1 mL of average fresh normal
plasma, collected from a large number of doners in several laboratories. The first International
Standard (IS) was calibrated by assay against fresh normal plasma from 315 donors. Subsequent
International Standards were calibrated against the previous IS, and also checked against fresh
normal plasma from a similar large number of donors to avoid the possibility of long-term drift of the
International Unit.
92. PARTICIPANTS
2.1 Preparation and ampouling of materials
- National Institute for Biological Standards and Control, Potters Bar UK
2.2 Homogeneity and stability testing
- National Institute for Biological Standards and Control, Potters Bar UK
2.3 Certification measurements (14 laboratories, 10 countries)
- Department of Haemostasis, Finnish Red Cross Blood Transfusion Service, Helsinki FI
- Department of Clinical Chemistry and Blood Coagulation, Karolinska Hospital,
Stockholm SE
- Department of Haematology, Royal Hallamshire Hospital, Sheffield UK
- Department of Transfusion Medicine and Coagulation, University of Freiburg, Freiburg DE
- Service d'Hematologie Biologique, Hopital Antoine Beclere, Paris FR
- Department of Haematology, University of Wales College of Medicine, Cardiff UK
- Department of Hematology, S Bortolo Hospital, Vicenza IT
- Haemostasis and Thrombosis Research Unit, University Hospital, Leiden NL
- Laboratoire d'Hemostase, Cliniques Universitaires Saint-Luc, Brussels BE
- Coagulation Unit, St James's Hospital, Dublin IR
- Regional Haemophilia Centre, The Royal Infirmary, Edinburgh UK
- Centro Emofilia e Trombosi "A Bianchi Bonomi", Isituto Medicina di Milano, Milano IT
- University Hospital Aarhus/Skejby, Haemophilia Centre and Coagulation Laboratory
Aarhus DK
- National Institute for Biological Standards and Control, Potters Bar UK
2.4 Statistical analysis
- National Institute for Biological Standards and Control, Potters Bar UK
Participants for the certification exercise were selected on the basis of their known expertise and
lengthy experience in FVIII assays and on the basis of their involvement and interest in
standardisation and quality control. Several of the participants had previously taken part in
international collaborative studies on FVIII.
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3. PRELIMINARY STUDIES
FVIII reference plasmas for the United Kingdom and for WHO have been manufactured at
NIBSC for over 20 years and previous studies have identified the important aspects of plasma
processing necessary to preserve the biological activity of FVIII and produce a stable standard (1,
3, 4).
These are:
(a) use of fresh plasma rather than frozen;
(b) collection by centrifugation from whole blood rather than by plasmapheresis;
(c) use of a second centrifugation step to eliminate residual cells;
(d) buffering of plasma as soon as possible after collection.
No additional preliminary studies were therefore undertaken and these were the conditions used to
collect and process the material for the European Reference Plasma for FVIII (BCR-629).
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4. PREPARATION OF THE CANDIDATE REFERENCE PLASMA
4.1 Justification for the choice of material
Routine measurement of FVIII on patients' plasma samples is carried out on freshly collected
citrated plasma. The ideal reference material should therefore consist of fresh citrated plasma.
However, practical considerations of stability, transport and storage make the use of fresh or frozen
plasma impossible, and all International and National reference plasmas for FVIII consist of
lyophilised plasma.
NIBSC has over 20 years' experience in the production of stable reference plasmas for FVIII and
therefore the procedures which were previously successful have been adopted (1, 3, 5).
4.2 Collection and processing of plasma
Fresh blood was collected on 3 August 1995 from 17 donors at the North London Blood
Transfusion Centre, Colindale, UK, into citrate phosphate dextrose-adenine anticoagulant at a ratio
of 63 mL anticoagulant to 450 mL blood. All units of plasma used to prepare the reference plasma
were tested and found negative for Hepatitis B surface antigen, antibodies to Hepatitis C and
antibodies to HIV 1 and 2. After the first centrifugation of 4200 rpm for 10 minutes at 22 °C, each
unit of plasma was buffered by the addition of 10 mL 1.0 mol/L HEPES, giving a final HEPES
concentration of approximately 0.05 mol/L, then centrifuged again under the same conditions. After
overnight storage at 4 °C the individual donations were pooled in a large filling vessel with constant
stirring, and filled into approximately 3,600 glass ampoules.
4.3 Ampoule filling and freeze-drying
Ampoule filling, freeze-drying and secondary desiccation were carried out according to the
conditions used for the preparation of International Biological Standards (5). The candidate
reference plasma was filled on 4 August 1995 into approximately 3,700 transparent glass ampoules,
coded 95/540, at a volume of 1.0 mL per ampoule. Filling was carried out at a temperature of 4 °C.
Check weighing was carried out at frequent intervals during the fill to check for constancy of fill
volume (see section 5.1) and the filling sequence was identified by numbering of ampoules. The
freeze-drying cycle of 5 days was followed by secondary desiccation over phosphorous pentoxide
for 6 days before the ampoules were sealed under dry nitrogen and stored at –20 °C. The number of
ampoules taken into stock was 3,689.
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5. TESTING OF HOMOGENEITY AND STABILITY
5.1 Homogeneity Tests
5.1.1 Check weights during ampoule filling
Check weight ampoules were included at every 50th position in the fill sequence. The balance
used for measuring the check weights was calibrated with an accuracy of ± 0.1 mg for a 1.0 g
standard checkweight by an organisation accredited by the United Kingdom National Measurement
Accreditation Service. The criterion of acceptability for filling plasma standards is an overall CV of
less than 0.75%, this is checked on a rolling basis during the fill.
The mean content of 76 ampoules checked during filling was 1.0307 g, with a range of 1.0171 g to
1.0541 g and a CV of 0.61% and 95% confidence limits of ± 1.22%. Individual check weight values
are given in Table 5.1 and shown graphically in Figure 5.1.
Figure 5.1 - Check weights during ampoule filling.
Lines indicate the mean mass ( ______ ) and +/- 1% of the mean mass (------ )
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Table 5.1 - Check weights during ampoule filling of BCR-629
Checkweight no Weight (g) Checkweight no Weight (g) Checkweight no Weight (g) Checkweight no Weight (g)
1 1.0541 21 1.0171 41 1.0285 61 1.0286
2 1.0350 22 1.0334 42 1.0290 62 1.0393
3 1.0295 23 1.0235 43 1.0387 63 1.0275
4 1.0326 24 1.0274 44 1.0289 64 1.0292
5 1.0231 25 1.0270 45 1.0295 65 1.0288
6 1.0290 26 1.0296 46 1.0297 66 1.0287
7 1.0321 27 1.0407 47 1.0282 67 1.0293
8 1.0287 28 1.0279 48 1.0301 68 1.0396
9 1.0212 29 1.0239 49 1.0379 69 1.0291
10 1.0262 30 1.0284 50 1.0288 70 1.0279
11 1.0212 31 1.0437 51 1.0297 71 1.0294
12 1.0289 32 1.0464 52 1.0280 72 1.0290
13 1.0258 33 1.0278 53 1.0293 73 1.0301
14 1.0402 34 1.0296 54 1.0287 74 1.0286
15 1.0227 35 1.0291 55 1.0393 75 1.0435
16 1.0331 36 1.0305 56 1.0294 76 1.0447
17 1.0250 37 1.0393 57 1.0281
18 1.0222 38 1.0291 58 1.0284
19 1.0264 39 1.0300 59 1.0291
20 1.0406 40 1.0295 60 1.0290
5.1.2 Mass
The mass of the freeze-dried plasma was estimated in six randomly selected ampoules. The
mass was obtained by subtracting the mass of the washed and dried empty ampoule from the mass
of the ampoule containing the freeze-dried plug (Table 5.2). Mean content of 6 ampoules was 85.4
mg, with a range of 84.6 mg to 86.0 mg and a coefficient of variation of 0.74%. The measured inter-
ampoule variability also includes variability introduced during the washing and drying of the ampoules
and is therefore probably an overestimate.
Table 5.2 - Masses of 6 ampoules of the freeze-dried candidate reference plasma BCR-629
Ampoule N° Total mass (g) Mass of empty Mass of Material
1 6.1915 6.1055 0.0860
2 6.2132 6.1273 0.0859
3 6.2157 6.1310 0.0847
4 6.2268 6.1409 0.0859
5 6.1531 6.0678 0.0853
6 6.2280 6.1434 0.0846
Mean 0.0584
Standard Deviation 0.00632
CV 0.74 %
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5.1.3 APTT testing
Since assay methods for Factor VIII have CVs in the range 5% to 10% these are not suitable
for homogeneity testing. It was therefore decided to adopt a different test, which has reduced
variability, the activated partial thromboplastin time (APTT) (6). The APTT forms the basis of the
one-stage FVIII clotting method in that the end-point clotting time is dependent on the same
coagulation pathway. The APTT test result is an absolute measurement of clotting time and is
therefore not calibrated relative to any reference material. For the homogeneity testing APTT
measurements were carried out on 21 randomly selected ampoules and also on 21 identical aliquots
of a frozen normal plasma. The results are shown in Table 5.3. Results from the tests on the identical
aliquots of frozen normal plasma indicate that the variability of the method (GCV%) is 0.97%
(n=21). The inter-ampoule variability of BCR-629 (GCV 0.80%) was slightly less than the variability
between the identical aliquots of the frozen normal plasma (GCV 0.97%). The fact that the CV for
BCR-629 is no greater than that of the identical frozen aliquots indicates no detectable
inhomogeneity in BCR-629 by this method.
Table 5.3 - APTT measurements on the candidate reference plasma BCR-629
Mean APTT values for ampoules of BCR-629* Mean APTT values for frozen aliquots*
33.3 33.2 32.4 32.5
33.0 33.1 33.1 32.7
32.8 33.4 32.7 33.1
33.6 33.3 33.1 32.3
33.6 33.0 32.7 32.6
33.5 33.3 32.9 32.6
33.4 33.2 32.3 32.4
33.6 33.3 32.6 33.0
33.6 33.8 33.1 32.3
33.0 33.7 32.8 33.4
33.2 32.8
Mean APTT
(seconds)
33.3 32.7
Range 32.8 - 33.8 32.3 - 33.4
GCV% 0.80 0.97
95% conf Limits 33.2 - 33.4 32.6 - 32.9
*Each APTT estimate is the mean from three replicate determinations on each ampoule or frozen aliquot.
5.2 Stability Testing
5.2.1 Residual moisture
Residual moisture was determined by Karl Fischer titrimetry with an uncertainty value (CV) of
5%; standardisation of the moisture meter was achieved using a check solution, provided by a
UKAS accredited organisation, containing a known amount of water in methyl cellulose. Previous
experience indicates that long-term stability of biological reference preparations requires low residual
moisture. In order to achieve low residual moisture the candidate reference plasma, BCR-629,
underwent both freeze-drying and secondary desiccation. Residual moisture was determined on
three randomly selected ampoules after freeze-drying and on another three ampoules after
completion of both freeze-drying and secondary desiccation. The levels of residual moisture given in
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Table 5.4 (<0.2%) are similar to those found with other International Reference Plasmas prepared
under the same conditions and indicate satisfactory processing of the candidate plasma preparation.
Table 5.4 - Residual moisture as mass fraction % in the candidate reference plasma BCR-629
after freeze-drying (FD) only and after both freeze-drying and secondary desiccation (FD+SD)
Sample No Moisture %
FD Only FD + SD
1
2
3
0.67
0.70
0.75
0.18
0.15
0.17
Mean 0.70 0.17
5.2.2 Accelerated degradation study
5.2.2.1 Design of the study
Estimates of the stability of the candidate reference plasma BCR-629 have been obtained
from accelerated degradation studies. Ampoules of the candidate reference plasma, BCR-629, were
stored at elevated temperatures (+4 ,+20 ,+37 ,+45 oC) for various periods before the estimation of
potency relative to ampoules stored at –20 oC. This data has been used to predict the stability of the
candidate reference plasma BCR-629 when stored at the bulk storage temperature of –20 oC from
the Arrhenius equation (7). Potency estimation was carried out using the one-stage clotting method
for FVIII with a variability (GCV) of 5%. The stability study was carried out in two exercises - a
short-term study with samples tested after 3 and 6 months storage and a longer term study with
samples tested after 33 months storage.
5.2.2.2 Results and discussion
Sampling times together with the residual potency of samples stored at elevated temperatures
are given in Table 5.5. Predicted degradation rates are given in Table 5.6. For ampoules stored at –
20 oC (bulk storage temperature) the predicted losses were 0.013 and 0.102% loss per year from
the short- and long-term studies, respectively. The result obtained from the long-term storage should
be considered a more reliable estimate since this has been extrapolated from degradation measured
at temperatures to which the candidate reference plasma BCR-629 may be exposed during transport
and use albeit transiently. These values are typical for those found with other reference plasmas for
FVIII and, indicate that the candidate reference plasma BCR-629 is suitably stable for long-term use
when stored at –20 oC. The results also indicate that, for most dispatches within Europe, special
arrangements to conserve temperature during mailing should not be necessary.
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Table 5.5 - Residual potency of accelerated degradation samples
Residual potency (% of –20 oC ampoules)Storage time
(months) +4 +20 +37 +45
0.5 ----- ----- ----- 94, 78, 82, 87
3 ----- ----- 60, 61, 61 26, 27, 33
6 101, 104, 97, 105 97, 90, 87, 88 54, 59, 39, 39 -----
33 90, 91, 91, 95 83, 86, 79, 81 40, 50, 31, 31, -----
Results are single estimates of FVIII from individual ampoules
Table 5.6 - Predicted degradation rates for the candidate reference plasma BCR-629 based on
the short-term (3 and 6 months storage) and long-term accelerated degradation study (33
months)
Predicted degradation rates (% loss per year)Storage
temperature
(oC)
Short-term study
(3 and 6 months storage)
Long-term study
(33 months storage)
-20 0.013 0.102
+4 1.145 1.606
+20 14.002 7.650
5.2.3 Real-time stability studies
Real-time stability of the candidate reference plasma was investigated by comparing estimates
of FVIII obtained in September 1999 with estimates obtained in the same laboratory (study code 9)
during the original calibration exercise in December 1995. Estimates of FVIII, at both times, were
carried out on 4 ampoules according to instructions distributed to the participants using the same
methodology (chromogenic method), instrumentation (ACL 3000 plus) and reference preparation
(3rd International Standard FVIII/vWF plasma 91/666).
There was no significant difference (unpaired t test) between the FVIII estimates from both time
points (data not shown). As a further check on long-term stability it is recommended that samples of
the reference plasma stored at –20 °C be assayed against samples stored at –70 °C.
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6. CERTIFICATIONS MEASUREMENTS
6.1 Principle of calibration
Calibration of the candidate reference plasma BCR-629 involved the estimation of FVIII
relative to the established primary reference preparation for FVIII in plasma (WHO 3rd International
Standard Factor VIII/vWF plasma, 91/666). This standard has an assigned value of 0.80 IU per
ampoule which is traceable to the original definition of the International Unit in fresh pooled normal
plasma (see section 1.3).
6.2 Materials
The following materials were included in the study, coded as indicated:
A 3rd IS Factor VIII/vWF Plasma (91/666)
B Proposed European Reference Plasma BCR-629
H House Standard (where available)
Four ampoules of A and B were provided by NIBSC for each laboratory, with one or 2 additional
sets of 4 ampoules for laboratories performing 2 and 3 methods, respectively. House standards were
provided locally, and were either commercial reference plasmas or local plasma pools - all had been
calibrated against the 3rd IS Factor VIII/vWF plasma (91/666) and were included so that
laboratories could check their local calibration procedure.
6.3 Assay design
The participants were asked to follow one of 3 assay designs depending on the number of
samples they were able to include in a single assay. Each design involved the performance of 4
independent assays of 6, 5 or 4 samples. For each sample at least 3 different dilutions of each
plasma were requested. The number of days for the assays was not specified as each assay is
independent, but in practice most laboratories performed the assays over more than one day.
Within an individual assay one, 2 or all 3 (where 4, 5 or 6 samples were included) of the
preparations were repeated which enabled a measure of the variability within the assay to be
obtained. Participants were requested to use their normal in-house validated one-stage, two-stage or
chromogenic method for FVIII:C.
6.4 Analytical methods
Some laboratories performed more than one method, giving a total of 19 data sets, each of which
was analysed individually. A description of the methods used by each laboratory is given in Table
6.1. Twelve laboratories performed the one-stage clotting method. This method is very similar to the
APTT used in the homogeneity test (section 5.3). The APTT measures the clotting time of normal
plasma in the presence of activators (APTT reagent) whereas the one-stage clotting method for
FVIII measures the ability of added FVIII (test sample) to shorten the clotting time of a FVIII-
deficient plasma in the presence of activators. Participants used a wide variety of APTT reagents,
FVIII-deficient plasmas and instrumentation.
Three laboratories performed the two-stage method based on the principle that the first-stage
incubation mixture produces an amount of the enzyme factor Xa which is proportional to the amount
of FVIII in the mixture; the amount of factor Xa is then estimated in the second stage by the clotting
time on addition of normal plasma.
Four laboratories performed the chromogenic method, using commercial kits from either
Chromogenix or Immuno. This method is based on the same principle as the two-stage method,
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except that more purified reagents are used in the first stage and the amount of FXa generated is
estimated by chromogenic substrate assay.
Table 6.1 - Assay methods used in the collaborative study
Lab.
no.
one-stage (a)
reagent      def-plasma   instrument
two-stage (b)
reagents instrument
chromogenic (c)
reagents          instrument
1 IL IL ACL ---- ---- ---- ----
2 IL Local SHP ACL ---- ---- ---- ----
3 IL IL ACL ---- ---- ---- ----
4 Organon local SHP MLA ---- ---- ---- ----
5 ---- ---- ---- in house ACL ---- ----
6 Dade Dade S&G Immuno S&G Immuno microtitre
7 Organon local SHP ACL ---- ---- Chromogenix microtitre
8 ---- ---- ---- ---- ---- Chromogenix Cobas Mira
9 IL Organon ACL in house ACL Chromogenix ACL
10 Diagen Immuno Sysmex ---- ---- ---- ----
11 Organon Organon Hemolab ---- ---- ---- ----
12 Dade Dade ACL ---- ---- ---- ----
13 Dade Local SHP MLA ---- ---- ---- ----
14 Stago Stago Stago ---- ---- ---- ----
Key to abbreviations:
IL - Instrumentation Laboratory;  ACL - IL Automated Coagulation Laboratory
S&G - Schnitger and Gross coagulometers;  SHP - severe haemophilic plasma
MLA – Medical Laboratory Analyser
6.5 Statistical analysis of the data
From the measurements of clotting times or optical densities of individual dilutions of the test
plasma, potencies in each assay were calculated by comparative bioassay against the 3rd
International Standard Factor VIII/vWF plasma (91/666), using well-established statistical methods
based on parallel line analysis (8). This analysis relies in the comparison of linear and parallel dose-
response relationships for the standard and test materials. Since an extreme range of dilutions of
assay samples gives a sigmoid dose-response relationship, it is sometimes necessary to omit one or
more responses from either end of the dilution range in order to achieve a linear dose-response.
For the majority of laboratories the untransformed response against the log of the dose was
considered. For the 3 laboratories using the chromogenic assay method (6c, 7c and 9c) and also for
laboratory 10a, the log transformation of the response was used to ensure parallelism and linearity.
For 3 laboratories it was necessary to omit some of the observations to achieve parallelism and
linearity as detailed:
- Lab 6a - for assay 2 the result for the highest dose of preparation A is omitted,
- Lab 6b - for assay 1 the results for preparation B are omitted,
- Lab 7c - the results for assay 1 are omitted.
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After the above transformations and amendments the assumptions of parallelism and linearity held in
96% and 85% of cases, respectively. Where the assumptions still did not strictly hold the
irregularities were not considered severe enough to require any further changes to be made.
Laboratory 8 reported results as potencies of single dilutions against an external standard and
therefore no statistical analysis could be performed. Potencies were calculated but not included in the
overall means.
Combined potency estimates were calculated for each laboratory across all assays by taking the
geometric mean of the results from all assays. Potency estimates by method and overall were
obtained by taking the appropriate geometric means of the laboratory means.
The geometric coefficient of variation (GCV%) provided a measure of the variability within and
between laboratories (9).
6.6 Results of the calibration
Table 6.2 shows the potency estimates together with 95% confidence limits and GCVs in
individual laboratories for the candidate reference plasma BCR-629. There was good agreement
within laboratories with all GCVs less than 9% except for laboratory 9a where the individual assay
results were highly variable. Since this data set was atypical in its variability it was not included in the
overall means. Inclusion or exclusion of the data from laboratory 9a did not affect the overall mean
value of 0.70 IU per mL. The potency estimates are also shown graphically in the histogram (Figure
6.1).
Table 6.3 shows the estimated potencies of the proposed European Standard according to the assay
technique used. The results show that the one- and two-stage methods give very comparable results
while that obtained when the chromogenic method is used is somewhat lower.
The potency estimates for the proposed European Standard for the individual laboratories range
from 0.65 to 0.77 IU per ampoule. The overall potency estimate across all the laboratories is 0.70
IU per ampoule with a GCV of 4.83% and 95% confidence limits of 0.68 - 0.72 IU per ampoule.
Table 6.2 - Estimated mean potencies in IU per ampoule, from individual laboratories, for the
candidate reference plasma BCR-629 with 95% confidence limits and GCV.
Laboratory Individual potency
estimates
(IU/ampoule)
Mean Potency
(IU/ampoule)
95% Confidence Limit GCV (%)
1a 0.65, 0.70, 0.68, 0.68 0.67 0.64 - 0.71 3.04
2a 0.84, 0.74, 0.78, 0.71 0.77 0.69 - 0.85 7.16
3a 0.73, 0.72, 0.80, 0.79 0.76 0.70 - 0.83 5.65
4a 0.78, 0.68, 0.73, 0.66 0.71 0.63 - 0.80 7.65
5b 0.72, 0.71, 0.68, 0.71 0.71 0.68 - 0.73 2.15
6a 0.66, 0.69, 0.73, 0.68 0.69 0.65 - 0.74 4.73
6b 0.70, 0.72, 0.72 0.72 0.69 - 0.75 1.72
6c 0.64, 0.68, 0.76, 0.65 0.68 0.60 - 0.77 8.10
7a 0.73, 0.71, 0.68, 0.67 0.70 0.66 - 0.74 3.79
7c 0.68, 0.62, 0.71 0.67 0.56 - 0.80 7.29
9b 0.68, 0.81, 0.72, 0.79 0.75 0.66 - 0.85 8.52
9c 0.65, 0.68, 0.59, 0.68 0.65 0.59 - 0.72 6.80
20
Laboratory Individual potency
estimates
(IU/ampoule)
Mean Potency
(IU/ampoule)
95% Confidence Limit GCV (%)
10a 0.68, 0.67, 0.70, 0.66 0.68 0.65 - 0.70 2.43
11a 0.69, 0.70, 0.67, 0.70 0.69 0.67 - 0.71 1.79
12a 0.70, 0.67, 0.79, 0.73 0.72 0.65 - 0.81 7.27
13a 0.72, 0.67, 0.67, 0.66 0.68 0.64 - 0.73 4.13
14a 0.69, 0.67, 0.73, 0.63 0.68 0.62 - 0.75 6.07
Key to methods:  a - one stage, b - two stage, c - chromogenic
N.B. data from laboratories 8 and 9a are not included for reasons given in the text
Figure 6.1 - Mean potency estimates (IU per ampoule) from individual laboratories for the
candidate reference plasma BCR-629
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Table 6.3 - Estimated potencies in IU per ampoule with GCV and 95% confidence limits
according to the assay method used
Method Mean Potency
(IU per ampoule)
95% confidence limits GCV (%) n
One-stage (a) 0.70 0.68 - 0.73 4.73 11
Two-stage (b) 0.73 0.68 - 0.78 2.89 3
Chromogenic (c) 0.67 0.63 - 0.71 2.33 3
Overall 0.70 0.68 - 0.72 4.83 17
Table 6.4 shows the estimated potencies for the laboratory house standards, together with
confidence limits and GCVs. Where the laboratory provided a potency for their House Standard
these are also included.
Table 6.4 - Estimated potencies in IU per ampoule for the laboratory house standards with 95%
confidence limits, GCVs and the potency value supplied by the laboratory where given
Laboratory Estimated Potency
(IU/ampoule)
Laboratory Potency value
(IU/ampoule)
95% confidence limit GCV (%)
1a 0.79 - 0.74 - 0.83 3.79
2a 1.06 1.10 0.92 - 1.21 8.78
3a 0.98 - 0.95 - 1.02 2.40
4a 0.97 - 0.86 - 1.08 7.59
5b 0.65 - 0.60 - 0.71 5.26
6a 0.58 0.6 0.55 - 0.62 3.80
6b 0.62 0.6 0.59 - 0.65 3.14
6c 0.61 0.6 0.60 - 0.63 1.84
7a 1.03 1.05 0.98 - 1.07 2.63
7c 1.15 1.00 1.01 - 1.29 4.96
9a 0.63 0.63 0.48 - 0.82 18.01
9b 0.70 0.63 0.62 - 0.79 7.99
9c 0.58 0.63 0.55 - 0.61 3.55
10a 0.76 - 0.70 - 0.83 5.49
11a 0.92 - 0.84 - 1.00 5.55
12a 0.78 - 0.68 - 0.88 8.41
13a 1.02 - 0.90 - 1.15 7.88
14a 0.86 - 0.80 - 0.94 5.37
6.6 Technical discussion
The level of agreement on FVIII assays of the proposed European Standard compares favourably
with that found in other collaborative studies (1, 3, 4), both within and between laboratories. The
variability between assays (intra-laboratory) within the individual laboratories was generally low with
all except one laboratory having GCVs below 9% and eight laboratories having a GCV below 5%
(Table 6.2). Agreement between laboratories (inter-laboratory) was very good, with a GCV below
22
5% for the overall mean value (Table 6.3).
Differences between methods were not statistically significant (t-test, p>0.05). One phenomenon
which can cause assay discrepancies is activation of FVIII, which gives rise to elevated values in the
1-stage method, but not in the 2-stage or chromogenic methods. The fact that the one-stage potency
was slightly higher than that by the chromogenic method is unlikely to indicate activation of FVIII,
since the two-stage assay gave the same potency as the one-stage method, and it is more likely that
these small differences arise by chance.
Potencies of the laboratories' house standards mostly agreed well with those already assigned, where
these figures were available (Table 6.4), indicating that calibration of the house standards had been
performed accurately.
As the results of the study were quite straightforward, it was not considered necessary to hold a
meeting of participants. There were no critical comments on the report of the study and all
participants agreed that the candidate reference plasma BCR-629 was suitable to serve as the
European Reference Plasma for FVIII.
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7. CERTIFIED VALUES AND UNCERTAINTIES
On the basis of the results of the collaborative study and with the agreement of the
participants, the following certified values are obtained for reference plasma BCR-629:
Table 7.1 – Certified values for BCR-629
Material Mean potency1)
(IU per ampoule)
Uncertainty2)
(IU per ampoule)
No of accepted
results
BCR-629  Reference Plasma for Factor VIII 0.70 0.02 17
1)  This result is the unweighted geometric mean from 17 independent sets of results estimates
2)  
 This value is the half width of the 95% confidence interval the mean value in 1)
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8. INSTRUCTIONS FOR USE
8.1 Caution
This preparation is not for administration to humans. Each individual plasma donation and the
final freeze-dried reference preparation was tested for HBsAg and for antibodies to HCV and HIV
1 and 2 and found to be negative. However, as with all preparations of human origin, this material
cannot be assumed to be free from infectious agents. Suitable precautions should be taken in the use
and disposal of the ampoule and its contents.
8.2 Description of samples
The FVIII reference plasma consists of glass ampoules (labelled BCR-629) containing
approximately 1 mL aliquots of pooled fresh human plasma, that is buffered by the addition of N-[2-
Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] (HEPES) (1.0 mol/L pH 7.4) to a final
concentration of 0.05 mol/L and freeze-dried under conditions used for International Biological
Standards (1). Ampoules were filled with nitrogen gas before sealing.
8.3 Storage and reconstitution
Unopened ampoules should be stored at –20 oC or below. Allow ampoules to equilibrate to
room temperature before opening. Reconstitute the total contents of each ampoule of reference
plasma with 1.0 mL of distilled water. Do not attempt to weigh out any portion of the freeze-dried
material. Swirl gently to dissolve the contents and transfer to a plastic tube. Store at room
temperature during the period of the assay which should be within 2 hours of reconstitution.
8.4 Potency estimation of test samples
The plasma should be used as a reference material to determine the FVIII:C potency of test
samples. At least 3 dilutions of the reference plasma should be made and a standard curve
constructed. The potency of the test sample, also preferably at 3 dilutions, should be determined by
parallel line analysis or by direct interpolation from the standard curve.
8.5 Guidelines for use of BCR-629 in quality control
The reference plasma is intended to be used for a number of purposes:
a) To check commercial reference plasmas for accuracy.
b) To check local plasma pools from time to time during their shelf life.
c) To give a reference value to NEQAS samples - for this purpose it is recommended that a
small panel of laboratories (6-8) be used.
d) As a reference sample of known potency when a new method, or new reagents, are
introduced.
In general it is recommended that for these purposes 2 assays on each of 2 ampoules (minimum) are
performed. Criteria for acceptance of results should be based on local internal quality control
procedures. The CRM is not intended for use as a working standard, ie for direct assay of patients'
samples.
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Abstract
Assays of Factor VIII in clinical laboratories are subject to large variability and one of the sources of this
variability is the wide range of reference plasmas used. An International Standard for Factor VIII in plasma is
available from WHO but only in limited quantity. The aim of this project was to establish a European
Reference Plasma for Factor VIII, carefully calibrated against the WHO standard in a large collaborative study,
in order to improve quality control in European laboratories.
The European Reference Plasma for Factor VIII (BCR-629) consists of lyophilised normal human plasma,
pooled from 17 donors, in sealed glass ampoules. Prior to pooling and ampouling the plasmas were
centrifuged twice and buffered in order to enhance stability, according to previous studies.
BCR-629 has been calibrated for FVIII relative to the primary WHO International Standard for FVIII in plasma
(3rd International Standard Factor VIII/vWF, plasma code 91/666) in a collaborative study involving 14
laboratories in 10 countries. There was good agreement between laboratories and between the 1-stage and
chromogenic assay methods. Preliminary stability studies based on accelerated degradation predicted
satisfactory long term stability for the standard when stored at –20 oC, but further monitoring of stability in real
time will be performed.
The results of the calibration study indicated that preparation BCR-629 is suitable to serve as the European
Reference Plasma for Factor VIII.
The mission of the Joint Research Centre is to provide customer-driven scientific and technical
support for the conception, development, implementation and monitoring of European Union
policies. As a service of the European Commission, the JRC functions as a reference centre of
science and technology for the Community. Close to the policy-making process, it serves the
common interest of the Member States, while being independent of commercial and national
interests.
                                                                                                          
15
LA-NA-21061-EN-C
